NCT06096064 is a clinical trial in Unfractionated Heparin, sponsored by Methodist Health System.

Who is sponsoring NCT06096064?

NCT06096064 is sponsored by Methodist Health System.

What condition does NCT06096064 study?

NCT06096064 studies Unfractionated Heparin.

Is NCT06096064 still recruiting?

NCT06096064 is currently completed. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT06096064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients

Completed Last updated 24 March 2026

What this trial tests

trial in Unfractionated Heparin in 100 participants. Completed in 21 August 2023.

Timeline

31 October 2022

Primary endpoint
21 August 2023

21 August 2023

Quick facts

Lead sponsor	Methodist Health System
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	31 October 2022
Primary completion	21 August 2023
Estimated completion	21 August 2023
Sites	1 location across United States

Conditions studied

Unfractionated Heparin — all drugs for Unfractionated Heparin →

Sponsor

Methodist Health System — full company profile →

Who can join

Adults 18 to 75, any sex, with Unfractionated Heparin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Methodist Health System trials

Trials by the same sponsor.

NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
NCT07492758 — Management of Extremity Injuries Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06096064 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing